Key result
Elevated pre-ablation systemic immune-inflammation index is linked to ~14% higher AF recurrence per 100 units.
Why the study?
AF recurrence remains a major limitation after RFCA, especially in hypertensive patients, and the prognostic value of pre-ablation SII in this population is unclear.
Does pre-ablation systemic immune-inflammation index (SII) and blood pressure control status predict atrial fibrillation recurrence in hypertensive patients undergoing first-time RFCA?
Cohort (n=568)
No
Does pre-ablation systemic immune-inflammation index (SII) and blood pressure control status predict atrial fibrillation recurrence in hypertensive patients undergoing first-time RFCA?
Hazard Ratio: 1.138 (95% CI 1.086–1.192)
p-value: p=<0.001
Pre-ablation systemic immune-inflammation index combined with blood pressure control status strongly predicts AF recurrence after first-time ablation in hypertensive patients.
High SII with poor BP control was associated with post-ablation AF recurrence; leaves open prospective validation before clinical use.
Background: Atrial fibrillation (AF) recurrence remains a major limitation after radiofrequency catheter ablation (RFCA), especially in patients with hypertension. Systemic immune-inflammation index (SII) has emerged as a novel marker of systemic inflammation, yet its prognostic value in this population is unclear. Objective: To assess the predictive value of pre-ablation SII for AF recurrence and explore the modifying effect of blood pressure (BP) control status in hypertensive patients. Methods: In this retrospective cohort study, 568 hypertensive AF patients undergoing first-time RFCA were enrolled. Patients were stratified by SII quartiles and BP control status. Cox regression, ROC analysis, and restricted cubic spline modeling were used to evaluate associations with AF recurrence. Results: < 0.001). Patients with both high SII and poorly controlled BP had a > 4-fold increased risk (HR: 4.061). SII outperformed conventional markers and significantly improved model discrimination (C-statistic: 0.755). Conclusion: Pre-ablation SII is an independent and superior predictor of AF recurrence after RFCA in hypertensive patients, particularly when BP is poorly controlled. Combined assessment of SII and BP control may improve individualized risk stratification.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) conducted a cohort in Atrial fibrillation with comorbid hypertension (n=568). Systemic immune-inflammation index (SII) vs. Lower SII was evaluated on Atrial fibrillation recurrence (HR 1.138, 95% CI 1.086-1.192, p=<0.001). Elevated pre-ablation systemic immune-inflammation index was independently associated with an increased risk of atrial fibrillation recurrence (HR 1.138 per 100-unit increase), with a 4-fold higher risk when combined with poorly controlled blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: